Table 1.
Demographic and clinical characteristics of the study participants.
| Characteristics | Frail (N = 16) | Non-frail (N = 16) | P |
|---|---|---|---|
| Age (years)* | 83 ± 5 (range 72–94) | ||
| Race (% white) | 93.70% | ||
| Sex (% female) | 87.50% | ||
| Body mass index (kg/m2)* | 26.5 ± 5.5 | 27.1 ± 4.6 | 0.73 |
| Comorbid chronic conditions: | |||
| Total number of diagnosis* | 4.1 ± 1.7 | 4.0 ± 1.7 | 0.92 |
| Specific diseases: | |||
| Hypertension | 50.00% | 81.30% | |
| Osteoporosis | 43.80% | 37.50% | |
| Osteoarthritis | 43.80% | 31.30% | |
| Hypercholesterolemia | 25.00% | 18.80% | |
| Congestive heart failure (controlled) | 37.50% | 25.00% | |
| Hypothyroidism (compensated) | 31.30% | 31.30% | |
| Coronary heart disease (asymptomatic) | 18.80% | 25.00% | |
| Malignancy (reported cured) | 31.30% | 37.50% | |
| Medication usage: | |||
| Total number of medications* | 4.3 ± 1.9 | 3.8 ± 1.7 | 0.39 |
| Specific medications: | |||
| Aspirin | 37.50% | 31.30% | |
| b-Blockers | 43.80% | 31.30% | |
| Diuretics | 37.50% | 43.80% | |
| Calcium-channel blockers | 25.00% | 50.00% | |
| ACE inhibitors | 31.30% | 31.30% | |
| HMG-CoA reductase inhibitors | 31.30% | 25.00% | |
| Thyroid (T4) supplement | 31.30% | 31.30% |
*
Mean ± SD.